Brief: Day One Biopharmaceuticals Says First Patient Dosed In Phase 2 Monotherapy Study In Raf-Altered Solid Tumors
22/11/2021 12:06
Nov 22 (Reuters) - Day One Biopharmaceuticals Inc DAWN.O :
* DAY ONE BIOPHARMACEUTICALS INC - ANNOUNCES FIRST PATIENT
DOSED
IN PHASE 2 MONOTHERAPY STUDY IN RAF-ALTERED SOLID TUMORS
* DAY ONE BIOPHARMACEUTICALS-PHASE 1B/2 STUDY EVALUATING
DAY101 IN
COMBINATION WITH PIMASERTIB, DAY ONE'S MEK INHIBITOR, EXPECTED
TO BEGIN IN Q1 OF 2022
Source text for Eikon: ID:nGNX5Vhq74
Further company coverage: DAWN.O
((Reuters.Briefs@thomsonreuters.com;))